Dashboard
Manage Tickers

KYMR


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cracking-the-code-understanding-analyst-reviews-for-kymera-therapeutics
Cracking The Code: Understanding Analyst R...
09/09/2024 13:00:39

this-bjs-wholesale-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-monday
This BJ's Wholesale Analyst Is No Longer B...
08/26/2024 13:00:41

wolfe-research-upgrades-kymera-therapeutics-to-outperform-announces-65-price-target
Wolfe Research Upgrades Kymera Therapeutic...
08/26/2024 10:26:15

Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform and announces $6...

kymera-therapeutics-raises-225m-via-upsized-public-stock-offering-vs-prior-200m-at-4075share-to-boost-its-pipeline-of-preclinical-and-clinical-degrader-programs
Kymera Therapeutics Raises $225M Via Upsiz...
08/20/2024 06:46:11

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule med...

kymera-therapeutics-begins-public-offering-of-200m-of-shares-of-common-stock-and-in-lieu-of-common-stock-to-certain-investors-pre-funded-warrants
Kymera Therapeutics Begins Public Offering...
08/19/2024 20:02:52

All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition,...

morgan-stanley-maintains-equal-weight-on-kymera-therapeutics-raises-price-target-to-45
Morgan Stanley Maintains Equal-Weight on K...
08/14/2024 11:57:33

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price ta...

unveiling-6-analyst-insights-on-kymera-therapeutics
Unveiling 6 Analyst Insights On Kymera The...
08/12/2024 21:01:08

wells-fargo-maintains-equal-weight-on-kymera-therapeutics-raises-price-target-to-38
Wells Fargo Maintains Equal-Weight on Kyme...
08/12/2024 17:43:23

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price targe...

kymera-therapeutics-cash-balance-of-702m-expected-to-provide-cash-runway-into-first-half-of-2027
Kymera Therapeutics' Cash Balance Of $702M...
08/07/2024 11:02:57

kymera-therapeutics-q2-2024-gaap-eps-058-beats-072-estimate-sales-25650m-beat-12554m-estimate
Kymera Therapeutics Q2 2024 GAAP EPS $(0.5...
08/07/2024 11:01:48

xpeng--quantumscape-are-among-top-11-mid-cap-stocks-that-performed-well-last-week-july-7-july-13-details
XPeng & QuantumScape Are Among Top 11 Mid ...
07/14/2024 17:22:37

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...

oppenheimer-maintains-outperform-on-kymera-therapeutics-maintains-52-price-target
Oppenheimer Maintains Outperform on Kymera...
07/10/2024 17:49:15

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and maintains $52 price target.

b-riley-securities-maintains-neutral-on-kymera-therapeutics-raises-price-target-to-36
B. Riley Securities Maintains Neutral on K...
07/09/2024 17:59:41

B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Neutral and raises the price tar...

why-helen-of-troy-shares-are-trading-lower-by-around-30-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Helen of Troy Shares Are Trading Lower...
07/09/2024 16:59:31

nvidia-micron-arlo-technologies-and-other-big-stocks-moving-higher-on-tuesday
Nvidia, Micron, Arlo Technologies And Othe...
07/09/2024 14:05:05

kymera-intends-to-expand-hidradenitis-suppurativa-and-atopic-dermatitis-phase-2-trials-to-more-rapidy-progress-towards-pivotal-studies-following-interim-review-of-safety-and-efficacy
Kymera Intends To Expand Hidradenitis Supp...
07/08/2024 20:06:22

cracking-the-code-understanding-analyst-reviews-for-kymera-therapeutics
Cracking The Code: Understanding Analyst R...
06/17/2024 12:00:57

hc-wainwright--co-reiterates-buy-on-kymera-therapeutics-maintains-46-price-target
HC Wainwright & Co. Reiterates Buy on Kyme...
06/17/2024 10:52:48

HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...

kymera-therapeutics-shares-new-clinical-data-from-its-ongoing-kt-333-phase-1-trial-data-were-presented-at-european-hematology-association-eha-annual-meeting
Kymera Therapeutics Shares New Clinical Da...
06/14/2024 11:21:47

hc-wainwright--co-reiterates-buy-on-kymera-therapeutics-maintains-46-price-target
HC Wainwright & Co. Reiterates Buy on Kyme...
06/03/2024 10:54:19

HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION